An observational study in Poor Performance Status, sponsored by Wolfson Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2011-07-06.
Sponsored by Wolfson Medical Center · Observational
The investigators will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.
Minocycline, a semisynthetic second generation derivative of tetracycline, was shown to have a clear beneficial neuroprotective effect in animal models of multiple sclerosis, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Animal models provide promising evidence of minocycline's ability to improve outcomes in an animal stroke model.
In light of these findings, we will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.
214 studies on the registry are indexed under Hemorrhagic Stroke; 84 are open to participants now.
This study's planned enrollment of 150 is below the median of 300 across 64 observational studies indexed under Hemorrhagic Stroke.
Browse Hemorrhagic Stroke studies →Wolfson Medical Center is the lead sponsor of 113 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
150 patients after acute hemorrhagic stroke. Half treated with Minocycline.
Patients with acute hemorrhagic stroke
Exclusion Criteria:
This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wolfson Medical Center